Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Corcept Therapeutics Inc is poised for significant growth, with annual sales for Korlym expected to increase by 19% to 26% year-over-year, driven by robust underlying demand despite recent commercial challenges. The anticipation of market expansion, especially in the Cushing's syndrome market and the promising sales trajectory for relacorilant, suggests potential peak sales of approximately $1.9 billion by 2031. Furthermore, the company’s proactive strategy to launch relacorilant with a dedicated sales force indicates confidence in capturing market share, further enhancing its growth prospects.

Bears say

Corcept Therapeutics's outlook has been negatively influenced by the issuance of a Complete Response Letter (CRL) regarding the delayed launch of relacorilant for the treatment of Cushing's Syndrome, resulting in a substantial decrease in share prices from previous highs. The downward revision of the 12-month price target from $145 to $90 per diluted share reflects the significant investor concerns surrounding future revenue projections, particularly with anticipated delays in product launches. Moreover, the company's reliance on relacorilant and its associated safety profile, coupled with market apprehensions regarding the launch of new therapies, underscores the risks that may weigh heavily on Corcept's financial performance moving forward.

Corcept Therapeutics (CORT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 5 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $114.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $114.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.